Early and locally advanced breast cancer. Diagnosis and treatment.

GUIDELINE TITLE
Early and locally advanced breast cancer. Diagnosis and treatment.

BIBLIOGRAPHIC SOURCE(S)
National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and treatment. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Feb. 37 p. (NICE clinical guideline; no. 80).

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates previous versions: National Institute for Health and Clinical Excellence (NICE). Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. London (UK): National Institute for Health and Clinical Excellence (NICE); 2006 Aug. 23 p. (Technology appraisal guidance; no. 107).

National Institute for Health and Clinical Excellence (NICE). Paclitaxel for the adjuvant treatment of early node-positive breast cancer. London (UK): National Institute for Health and Clinical Excellence (NICE); 2006 Sep. 18 p. (Technology appraisal guidance; no. 108).

National Institute for Health and Clinical Excellence (NICE). Docetaxel for the adjuvant treatment of early node-positive breast cancer. London (UK): National Institute for Health and Clinical Excellence (NICE); 2006 Sep. 21 p. (Technology appraisal guidance; no. 109).

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

December 16, 2008 - Antiepileptic drugs: The U.S. Food and Drug Administration (FDA) has completed its analysis of reports of suicidality (suicidal behavior or ideation [thoughts]) from placebo-controlled clinical trials of drugs used to treat epilepsy, psychiatric disorders, and other conditions. Based on the outcome of this review, FDA is requiring that all manufacturers of drugs in this class include a Warning in their labeling and develop a Medication Guide to be provided to patients prescribed these drugs to inform them of the risks of suicidal thoughts or actions. FDA expects that the increased risk of suicidality is shared by all antiepileptic drugs and anticipates that the class labeling change will be applied broadly.

abrir aquí para acceder al documento AHRQ NGC completo:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=14312&nbr=&string=